特应性皮炎
神话学
医学
皮肤病科
家庭医学
替代医学
历史
经典
病理
摘要
The role of emollients as an early-life intervention for the primary prevention of atopic dermatitis (AD)/eczema has been hotly debated. It began with the recognition that the skin’s function as a barrier falters before AD develops. It is no big leap to suggest that repairing the skin barrier defect might prevent the onset of AD. Naturally, emollients, the traditional bedrock of AD treatment, were turned to as a ready intervention. More than 35 studies involving > 6000 babies have now been conducted to determine whether the regular application of emollients during the first months of life can prevent or delay AD onset, with mixed results. A series of systematic reviews have scrutinized the results and come to varying conclusions.1–3 Yet, making conclusions is impeded by a stark absence of evidence on the effects of the interventions on the skin barrier directly, a crucial aspect of the underlying concept. In this issue of the BJD, Rehbinder et al. present a follow-up report on the negative PreventADALL study, which reveals the effects of the intervention on the skin barrier. Involving 2397 babies, this is by far one of the most influential AD prevention studies. The intervention consisted of four baths weekly with a specially formulated emulsified oil and a daily emollient cream applied to the face from 2 weeks of age for 8 months. Skin barrier function was measured indirectly as transepidermal water loss (TEWL) at 3, 6 and 12 months. TEWL was significantly higher at 3 months in the intervention group compared with the control (no intervention) group, revealing a disruptive effect of the emollient intervention on the condition of the skin barrier. Meta-analysis by Kelleher et al. reported an increased risk of AD associated with this intervention vs. the control.3 While this was not the outcome expected, it does demonstrate the importance of the skin barrier and its role in AD development.
科研通智能强力驱动
Strongly Powered by AbleSci AI